Next Science

Next Science ROE

Delisted

The Return on Equity (ROE) of Next Science (NXS.AX) as of Oct 31, 2026 is -307.51 %. In the previous year, Return on Equity (ROE) was -126.91 % — a change of 142.31% (lower).

ROE

-307.51 %

YoY

142.31%

Last updated:

In 2024, Next Science's return on equity (ROE) was -307.51 %, a 142.31% increase from the -126.91 % ROE in the previous year.

The Next Science ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2017
-36.63 USD
Jan 1, 2018
-3,405.38 USD
Jan 1, 2019
-74.12 USD
Jan 1, 2020
-62.98 USD
Jan 1, 2021
-86.84 USD
Jan 1, 2022
-157.84 USD
Jan 1, 2023
-126.91 USD
Jan 1, 2024
-307.51 USD
The Next Science ROE history
YEARROEYoY
-307.51 %+142.31%
-126.91 %-19.60%
-157.84 %+81.76%
-86.84 %+37.88%
-62.98 %-15.02%
-74.12 %-97.82%
-3,405.38 %+9,197.55%
-36.63 %-80.44%
-187.24 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Next Science Stock analysis

What does Next Science do? Next Science Ltd. generates revenue through the development and commercialization of its XBIO technology, which addresses bacterial biofilm-related infections in human health. The company's product portfolio includes XPERIENCE, a solution for preventing surgical site infections by rinsing away debris and microorganisms, and SurgX Sterile Antimicrobial Gel, designed to reduce surgical and post-surgical infections through sustained antibacterial action for up to five days. Blast X, an antimicrobial wound gel, targets bacterial infections in wounds. These products are sold to healthcare providers and medical facilities seeking effective solutions for bacterial biofilm eradication and infection prevention. The XBIO technology underpins all products, offering non-toxic efficacy against both biofilm and free-floating bacteria. XPERIENCE is used as a pre-surgical rinse, SurgX provides prolonged protection post-surgery, and Blast X treats existing wounds. Healthcare institutions, particularly hospitals and surgical centers, are the primary buyers, leveraging these products to enhance patient outcomes and reduce infection rates. Next Science Ltd. focuses on the healthcare sector, specifically targeting applications where bacterial biofilms pose significant risks. The company's products are positioned for use in surgical settings, wound care, and infection prevention protocols. By addressing critical needs in medical environments, the firm caters to healthcare providers who prioritize non-toxic, effective antimicrobial solutions for patient safety and operational efficiency. Next Science is one of the most popular companies on Eulerpool.

ROE Details

Decoding Next Science's Return on Equity (ROE)

Next Science's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Next Science's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Next Science's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Next Science’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Next Science stock

Return on Equity (ROE) of Next Science is -307.51 % in 2024.

Return on Equity (ROE) of Next Science changed from -126.91 % to -307.51 %, representing a 142.31% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Next Science since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Next Science with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Next Science

All Key Metrics — Next Science